سعر بيتافال 0.1% كريم 20 جم 2025

Egyptian Arab Drug Company topical corticosteroid cream containing betamethasone 0.1% (20 g tube).

• Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatosesPopulation: Adults and pediatric patients (with pediatric cautions)DailyMed (U.S. National Library of Medicine)

• Local reactions reported infrequently (may be more frequent with occlusion): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae and miliaria.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• History of hypersensitivity to any of the components of the preparation.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Systemic absorption of topical corticosteroids can produce reversible HPA axis suppression, Cushing's syndrome, hyperglycemia and glucosuria. Risk increases with potency, large surface area, prolonged use and occlusive dressings.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Pregnancy Category C (historical US labeling). Use during pregnancy only if potential benefit justifies potential risk to the fetus; do not use extensively, in large amounts, or for prolonged periods in pregnant patients.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Caution should be exercised when topical corticosteroids are administered to a nursing woman.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Betamethasone: Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions via intracellular glucocorticoid receptor-mediated gene regulation of inflammatory mediators. Percutaneous absorption increases with inflammation and occlusion.